Leadless Pacemaker–Assisted Non-Vascular ICD Arrhythmia Discrimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional implantable cardioverter defibrillators (ICDs) require transvenous leads and intracardiac electrodes, leading to complications such as lead system malfunction, infection, and increased cost, especially in children, and non-vascular ICDs face issues with under-sensing and susceptibility to noise, affecting arrhythmia discrimination.
Innovation Solution
A leadless pacemaker (LP) and non-vascular implantable cardioverter defibrillator (NV-ICD) system, where the LP senses near-field electrograms (NF-EGM) and paces the cardiac chamber, while the NV-ICD senses far-field electrograms (FF-EGM) and delivers shocks, with implant-to-implant (i2i) communication for improved arrhythmia discrimination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transvenous leads and intracardiac electrodes are used in conventional ICDs, then reliable intracardiac electrogram sensing is achieved, but lead system malfunction, fracture, and infection complications occur
Solution Approach 1:
The patent extracts the sensing function from the transvenous lead system by implanting a separate leadless pacemaker with sensing electrodes directly in the cardiac chamber. This separates the harmful lead system from the beneficial sensing function, eliminating lead-related complications while maintaining reliable electrogram detection through the leadless device's intracardiac electrodes.
Solution Approach 2:
The patent segments the ICD system into two independent components: a non-vascular ICD for shock delivery and a separate leadless pacemaker for sensing and pacing. This segmentation allows each device to be optimized for its specific function, with the leadless pacemaker providing reliable intracardiac electrogram sensing without the complications associated with transvenous leads.
2Object-affected harmful factors
If non-vascular ICDs use extracardiac electrodes to sense far-field electrograms, then transvenous lead complications are eliminated, but under-sensing of cardiac events and susceptibility to noise occur
Solution Approach 1:
The patent merges the advantages of both approaches by combining the leadless pacemaker's intracardiac electrogram sensing capability with the non-vascular ICD's shock delivery function. The leadless pacemaker provides high-fidelity intracardiac electrogram sensing free from transvenous lead complications, while the non-vascular ICD delivers shocks without requiring transvenous leads, thus eliminating lead complications while maintaining measurement precision.
Solution Approach 2:
The leadless pacemaker acts as an intermediary device that bridges the gap between conventional ICDs and non-vascular ICDs. It provides the high-quality intracardiac electrogram sensing that non-vascular ICDs lack, while communicating with the non-vascular ICD to enable arrhythmia detection and shock delivery without requiring the non-vascular ICD to perform its own intracardiac sensing.
3Reliability
If conventional ICDs use transvenous leads for electrode positioning, then effective arrhythmia treatment is achieved, but significant surgery and surgical skill are required
Solution Approach 1:
The patent segments the implantation procedure into two simpler steps: first implanting the leadless pacemaker through a minimally invasive approach, and then implanting the non-vascular ICD separately. This segmentation eliminates the complex transvenous lead positioning step, reducing the surgical skill requirement while maintaining effective arrhythmia treatment through the combined functionality of both devices.
Solution Approach 2:
The patent replaces the mechanical transvenous lead positioning system with a minimally invasive leadless pacemaker implantation system. The leadless pacemaker can be delivered through a catheter-based approach or similar minimally invasive technique, eliminating the need for surgical venous access and complex lead positioning, thus reducing surgical requirements while maintaining effective arrhythmia treatment.
4Device complexity
If non-vascular ICDs are used to reduce surgical complexity, then lead insertion surgery is simplified, but arrhythmia discrimination accuracy decreases due to under-sensing
Solution Approach 1:
The patent merges the simplified implantation advantage of non-vascular ICDs with the high measurement precision of intracardiac electrogram sensing by integrating a leadless pacemaker. The leadless pacemaker provides accurate intracardiac electrogram sensing for reliable arrhythmia discrimination, while the non-vascular ICD component maintains simplified implantation procedures, thus achieving both simplified surgery and accurate arrhythmia discrimination.
Data Source
AI summary
Methods, systems, and devices that detect an arrhythmic and/or perform arrhythmia discrimination are described. Such a system includes an LP that senses a NF-EGM, and a NV-ICD that senses a FF-EGM. The LP determines cardiac activity information based on at least the NF-EGM. The NV-ICD normally monitors for an arrhythmia and/or performs arrhythmia discrimination based on cardiac activity detected by the NV-ICD itself from the FF-EGM, without using cardiac activity information obtained from the LP. When the NV-ICD determines that an extracardiac signal is likely preventing the NV-ICD from accurately detecting cardiac activity based on the FF-EGM sensed by the NV-ICD, the NV-ICD sends i2i message(s) to the LP requesting that the LP provide cardiac activity information to the NV-ICD, based upon which the NV-ICD monitors for an arrhythmia and/or performs arrhythmia discrimination. The LP normally does not send i2i messages including the cardiac activity information to the NV-ICD.